Europe has a shot (pun) but less and less competitive, they do not have the VC and small biotech power of US which will dry up for vaccines. Discovery and clinical development are faster in China in general, the pharmas are now inlicensing from there.
February 13, 2026 at 4:37 PM
Europe has a shot (pun) but less and less competitive, they do not have the VC and small biotech power of US which will dry up for vaccines. Discovery and clinical development are faster in China in general, the pharmas are now inlicensing from there.
#AlzeCure #AlzeCurePharma #pain #paintherapy #ACD440 #NeuPSIG2025 #neuropathicpain #peripheralneuropathicpain #TRPV1antagonist #heatinducedpain #strategicinlicensing #inlicensing #painrelief #painkillers #opioidcrisis #painprecisionmedicine #chronicneuropathicpain
pharmatimes.com/news/alzecur...
pharmatimes.com/news/alzecur...
AlzeCure to present promising pain therapy ACD440 at NeuPSIG 2025 - PharmaTimes
Clinical results from phase 2 study highlight analgesic effects in neuropathic pain patients
pharmatimes.com
September 2, 2025 at 8:28 AM
"Adalta sees promise in new 'East to West' strategy for T-cell therapies "
#Health #Healthcare #ElderCare
#Health #Healthcare #ElderCare
Adalta sees promise in new 'East to West' strategy for T-cell therapies
Adalta Ltd. is outlicensing all of its internal products and focusing instead on inlicensing early stage T-cell assets from Asia, mostly from China, Adalta CEO Tim Oldham told BioWorld. Dubbed its “East to West” strategy, Adalta is integrating Asia's prowess in T-cell therapy development with the efficiency and quality of Australia's clinical and manufacturing ecosystem to create a pathway connecting Eastern innovation in cellular immunotherapies with Western regulated markets and patients.
www.bioworld.com
June 18, 2025 at 9:30 PM
"Adalta sees promise in new 'East to West' strategy for T-cell therapies "
#Health #Healthcare #ElderCare
#Health #Healthcare #ElderCare
#oncology #precisionmedicines #cancer #cancers #MosaicTherapeutics #Astex #AstexPharmaceuticals #inlicensing #oncologyprogrammes #clinicalstageoncologyprogrammes #combinationtherapies #biomarkers #drugdiscoveryplatform #clinicaltrials
pharmatimes.com/news/mosaic-...
pharmatimes.com/news/mosaic-...
Mosaic therapeutics expands pipeline with Astex deal - PharmaTimes
Cambridge firm in-licenses two oncology programmes
pharmatimes.com
May 6, 2025 at 2:33 PM
A more nuanced analysis of the China-inlicensing and "me-too, me-better" trends.
lifescivc.com/2025/01/a-ta...
lifescivc.com/2025/01/a-ta...
January 21, 2025 at 1:53 PM
A more nuanced analysis of the China-inlicensing and "me-too, me-better" trends.
lifescivc.com/2025/01/a-ta...
lifescivc.com/2025/01/a-ta...
The clinical pipeline is wildly saturated with GLP-1s and CD19-CD3 bispecific T cell engagers.
Why oh why is the new cool strategy inlicensing more of the same from China?? I do not get it.
Why oh why is the new cool strategy inlicensing more of the same from China?? I do not get it.
January 20, 2025 at 9:23 PM
The clinical pipeline is wildly saturated with GLP-1s and CD19-CD3 bispecific T cell engagers.
Why oh why is the new cool strategy inlicensing more of the same from China?? I do not get it.
Why oh why is the new cool strategy inlicensing more of the same from China?? I do not get it.